Manufacturing Today - Summer 2010 - (Page 92)
www.cambrex.com / HQ: East Rutherford, N.J. / Annual Sales: $236.3 million / Employees: 850 / Products: Pharmaceuticals Eric Neuffer, vice president : “Every department has a role in ensuring [our] products are delivered to our customers on time.”
behind-the-scenes advances in technology at cambrex help reduce risk for manufacturers. by marge d. hansen
cambrex corp. develops active ingredients for pharmaceutical makers.
acquired in 2008, provides custom organic synthesis and contract R&D. “Cambrex continues to focus on implementing strategies to grow our portfolio of late-stage clinical projects, long-term manufacturing agreements for approved branded and generic APIs and our drug delivery and controlled substances businesses,” President and CEO Steven M. Klosk says. “In addition, we are expanding our platform of products and services based on core proprietary technologies. For example, Cambrex’s most recent acquisition of IEP GmbH [in] Wiesbaden, Germany, in March 2010, has strengthened our biocatalysis platform for pharmaceutical drug development.”
A Competitive Edge
Due to operating in a heavily regulated market governed by the U.S. Food and Drug Administration (FDA) and other international regulatory organizations, quality and process are tightly controlled at Cambrex. Importation of certain controlled substances for pain management and central nervous system (CNS) indications into the United States is prohibited by federal law. As a manufacturer of controlled substances, Cambrex has positioned itself to take advantage of reduced international competition in the U.S. market for these products. However, domestic competition in this market is intense and its facilities must remain in strict compliance with the Drug Enforcement Administration’s (DEA) laws and licensure. “We work with the FDA and DEA
Over the past 29 years, Cambrex Corporation has strategically acquired complementary resources and technologies to achieve growth and success in manufacturing small molecule active pharmaceutical ingredients (APIs). Working with multinational and small or emerging pharmas, Cambrex excels in difficult areas of chemistry and has the experience to take customers through development, scale-up and the manufacture of commercial volumes of branded and generic bulk APIs. Cambrex’s North American locations include headquarters in East Rutherford, N.J., and its bulk active 92
manufacturing-today.com SUMMER 2010
pharmaceutical ingredients research, development and cGMP manufacturing operation – Cambrex Charles City Inc. – in Charles City, Iowa. The company focuses on high-energy reactions, biocatalysis and custom manufacturing at its Cambrex Karlskoga cGMP facility in Sweden. Alfred Nobel founded an explosives operation there, which became Nobel Chemicals AB and then Cambrex Karlskoga in 1994. Generic APIs are developed and manufactured under cGMP at Milan, Italy-based Cambrex Profarmaco. Cambrex Tallinn in Estonia, formerly known as ProSyntest Ltd. and
Table of Contents for the Digital Edition of Manufacturing Today - Summer 2010
Manufacturing Today - Summer 2010
Ultrafryer Systems Inc.
Wil-Rich LLC & Wishek MFG LLC
American Precision Fabricators
Aqua Products Inc.
Black Diamond Equipment
Columbian Home Products
Control Devices LLC
Endustra Filter Manufacturers Inc
Heil Trailer International
Professional Building Systems Inc.
Smart Start Inc
Ausco Products Inc.
Chapin International Inc.
Cleveland Gear Co.
Consolidated Precision Products
Control Flow Inc.
Douglas Autotech Corp.
Fetzer Architectural Products
The FNA Group
Fourslide Spring and Stamping Inc.
G.A. West & Company
Great Lakes Power Group
Grimm Brothers Plastics
Legends Furniture Inc.
National Tube Supply Co.
Optex Systems Inc.
V.E. Enterprises Inc
W. Soule & Company
Manufacturing Today - Summer 2010